Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada
NCT Number: NCT00907530
This study is being conducted as a phase IV, double-blind, multi-center, randomized, crossover trial aimed at a within-subject comparison of MULTIHANCE and GADOVIST at a dose of 0.1 mmol/kg, in terms of qualitative and quantitative assessment of unenhanced MRI (UE MRI) and contrast-enhanced MRI (CE MRI) for the visualization of brain disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Hamilton, Ontario, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
MULTIHANCE ® 0.5 M,0.1 mmol/kg
GADOVIST ® 1.0 M,0.1 mmol/kg
Time frame: Day 1 and Day 2
Bracco Diagnostics, Inc
Industry
Phase IV, Double-Blind, Multi-Center, Randomized, Crossover Study to Compare 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF GADOVIST® in Magnetic Resonance Imaging (MRI) of the Brain
Acronym: MERIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01849549
Brain Diseases, Brain Lesions
Rouen, France
View Trial DetailsNCT02559401
Brain Lesions
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT03528200
Brain Lesions
Charleston, South Carolina, United States
View Trial DetailsNCT01304576
Brain Diseases, Brain Lesions
Rouen, Haute-Normandie, France
View Trial Details